We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

If you are unable to listen to this audio, please update your browser or click here to download the file [147.0 MB]
“We need to debunk the myth that Africa cannot be a source of health innovation,” says Kelly Chibale, director of the Drug Discovery and Development Centre at the University of Cape Town, South Africa. He believes there should be more African-led drug research so that the continent is not just seen as a place where international researchers carry out clinical trials.

Chibale and his team helped identify a compound that could evolve into the first single-dose cure for Malaria. The compound is set to finish a phase 1 clinical trial next month and is the first of its kind to be developed in Africa. The compound, which seems to be more effective than chloroquine or artemisinin, could prove crucial at a time when drug resistance is becoming a threat in the continent and beyond.

Related topics